Drug Patents owned by Therapeuticsmd Inc
1. List of Annovera drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10780047 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(15 years from now) | |
| US10632066 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(15 years from now) | |
| US10765628 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(15 years from now) | |
| US10940157 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
| US11529308 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
| US10918649 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
| US10925882 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 10, 2023 |
Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient
NCE-1 date: 2022-08-10
Market Authorisation Date: 10 August, 2018
Treatment: Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception; Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles
Dosage: RING;VAGINAL
ANNOVERA family patents
11
United States
1
Korea, Republic of
1
Japan
1
Colombia
1
Israel
1
Chile
1
Australia
1
Argentina
1
Canada
1
China
1
Brazil
1
European Union
2. List of Bijuva drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033626 | THERAPEUTICSMD INC | Progesterone formulations having a desirable pk profile |
Nov, 2032
(9 years from now) | |
| US10639375 | THERAPEUTICSMD INC | Progesterone formulations |
Nov, 2032
(9 years from now) | |
| US11110099 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US8993548 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US11103516 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US10206932 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US8846649 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US8846648 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US9114146 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US9114145 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US10675288 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US9301920 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US8987237 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US9006222 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US10806740 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US11103513 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US8933059 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US11166963 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US8633178 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US10052386 | THERAPEUTICSMD INC | Progesterone formulations |
Nov, 2032
(9 years from now) | |
| US8993549 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient
Market Authorisation Date: 28 October, 2018
Treatment: Treatment of menopause symptoms, including vasomotor symptoms
Dosage: CAPSULE;ORAL
BIJUVA family patents
97
United States
20
Australia
18
Japan
13
European Union
11
Korea, Republic of
11
Canada
10
Mexico
8
Russia
8
Brazil
5
Argentina
4
Israel
2
Spain
2
Croatia
2
Hungary
2
Poland
1
Portugal
1
South Africa
1
Lithuania
1
RS
3. List of Imvexxy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537581 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US11246875 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US11241445 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US10835487 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US9289382 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US10806697 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US11351182 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US11304959 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
| US11497709 | THERAPEUTICSMD INC | NA |
Nov, 2032
(9 years from now) | |
| US10471072 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(10 years from now) | |
| US10568891 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(10 years from now) | |
| US10888516 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(10 years from now) | |
| US10668082 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(10 years from now) | |
| US11116717 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(10 years from now) | |
| US11065197 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(10 years from now) | |
| US11123283 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(10 years from now) | |
| US10258630 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(10 years from now) | |
| US9180091 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Dec, 2033
(10 years from now) | |
| US10398708 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(10 years from now) | |
| US11266661 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Feb, 2034
(10 years from now) | |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy; Treatment of moderate to severe dyspareunia
Dosage: INSERT;VAGINAL
IMVEXXY family patents
92
United States
19
Australia
17
Japan
12
European Union
10
Korea, Republic of
10
Canada
9
Mexico
8
Brazil
7
Russia
4
Argentina
4
Israel
2
Spain
2
Croatia
2
Hungary
2
Poland
1
Portugal
1
South Africa
1
Lithuania
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic